English▼
Press release originally published May 17, 2022 on Avrobio.com. New early data show key visual motor integration, visual perception...
Read moreBy Cystinosis Research Network
May 17, 2022
In honor of 5th Annual Cystinosis Awareness Day a new global initiative has been announced: the Cystinosis Warrior Impact...
Read moreBy Cystinosis Research Network
April 29, 2022
Leadiant, the makers of Cystaran eye drops, are opening up the floor for a Town Hall Q&A on Wednesday,...
Read moreBy Cystinosis Research Network
April 20, 2022
Clinical researchers from the Stanford Neuromuscular department are looking for individuals who have been diagnosed with Cystinosis Myopathy, to...
Read moreOn Wednesday, April 13, Leadiant Biosciences confirmed CYSTARAN eye drops are available for those who qualify. Along with a...
Read moreCould newborn screening provide a turning point in the natural history of cystinosis? Review the latest publication “Newborn Screening: Review of...
Read moreLeadiant Biosciences, Inc. received communication from the FDA that they have approved the new Cystaran bottle and manufacturer. Please...
Read moreData from the AVROBIO Phase 1/2 investigational gene therapy for cystinosis was released today at WORLDSymposium in San Diego....
Read moreThe Adult Leadership Advisory Board (ALAB) continues their podcast series “Cystinosis Rare: Journey Into the Unknown” with episode 8...
Read more
